title: Central Disorders of Hypersomnolence: Focus on the Narcolepsies and Idiopathic Hypersomnia.
abstract: The central disorders of hypersomnolence are characterized by severe daytime sleepiness, which is present despite normal quality and timing of nocturnal sleep. Recent reclassification distinguishes three main subtypes: narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia (IH), which are the focus of this review. Narcolepsy type 1 results from loss of hypothalamic hypocretin neurons, while the pathophysiology underlying narcolepsy type 2 and IH remains to be fully elucidated. Treatment of all three disorders focuses on the management of sleepiness, with additional treatment of cataplexy in those patients with narcolepsy type 1. Sleepiness can be treated with modafinil/armodafinil or sympathomimetic CNS stimulants, which have been shown to be beneficial in randomized controlled trials of narcolepsy and, quite recently, IH. In those patients with narcolepsy type 1, sodium oxybate is effective for the treatment of both sleepiness and cataplexy. Despite these treatments, there remains a subset of hypersomnolent patients with persistent sleepiness, in whom alternate therapies are needed. Emerging treatments for sleepiness include histamine H3 antagonists (eg, pitolisant) and possibly negative allosteric modulators of the gamma-aminobutyric acid-A receptor (eg, clarithromycin and flumazenil).
authors.affiliation: Emory Sleep Center, Emory University School of Medicine, Atlanta, GA.
authors.forename: Zeeshan
authors.initials: Z
authors.lastname: Khan
authors.affiliation: Emory Sleep Center, Emory University School of Medicine, Atlanta, GA. Electronic address: Lbecke2@emory.edu.
authors.forename: Lynn Marie
authors.initials: LM
authors.lastname: Trotti
mesh_terms: D006801:Humans; D020177:Idiopathic Hypersomnia / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D009290:Narcolepsy / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*